Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | EBP | Q15125 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625806 | 0.91 | DRD2 (0.53) | SIGMAR1TMEM97CYP1A2CYP2D6ADRA1D | |
| SCHEMBL5183582 | 0.91 | SIGMAR1 (0.54) | SIGMAR1TMEM97CYP1A2CYP2D6ADRA1D | |
| SCHEMBL5183557 | 0.90 | SIGMAR1 (0.56) | SIGMAR1TMEM97CYP1A2CYP2D6ADRA1D | |
| SCHEMBL6624881 | 0.86 | MAPK1 (0.47) | SIGMAR1TMEM97ADRA1DADRA1AADRA1B | |
| SCHEMBL5182166 | 0.86 | SIGMAR1 (0.53) | SIGMAR1TMEM97CYP1A2CYP2D6ADRA1D | |
| SCHEMBL5242704 | 0.83 | DRD2 (0.53) | SIGMAR1TMEM97ADRA1DADRA1AADRA1B | |
| SCHEMBL5182433 | 0.82 | DRD2 (0.56) | SIGMAR1TMEM97ADRA1DADRA1AADRA1B | |
| SCHEMBL5183526 | 0.82 | HSD17B10 (0.45) | SIGMAR1TMEM97CYP1A2CYP2D6ADRA1D | |
| SCHEMBL5241546 | 0.82 | DRD2 (0.52) | SIGMAR1TMEM97ADRA1DADRA1AADRA1B | |
| SCHEMBL2768860 | 0.81 | ADRA1D (0.61) | SIGMAR1TMEM97ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1729762-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |